VNDA Vanda: שולי רווח נקי

Vanda Pharma (VNDA) - לוגו תאגידי

Strategic partnerships and the acquisition of CNS licenses are driving growth for Vanda Pharmaceuticals (VNDA). Annual net margins visualize this effect, where -119.90 captures a new level. Developments in neurochemistry and sleep research strengthen the firm's position, although patent dependency and the battle against generics create certain risks despite a stable liquidity reserve.

Vanda (VNDA) - רווחיות מכירות נקייה מ-04.07.2022 עד 19.11.2026

Vanda (VNDA) - פילוחי מדדים ודוחות פיננסיים

- שער מניה ותחזית מחירי מומחים:
ניתוח כללי של החברה:Vanda Pharmaceuticals Inc. - VNDA
מוצרים מוגמרים של Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is integrating robotic molecule screening for CNS treatments, which is expected to optimize operating expenses and enhance overall business efficiency. Analyzing the level of commercial profitability, the investor assesses the net profit margin relative to total revenue, allowing for a determination of the company's actual ability to convert sales into bottom-line income and confirm the fundamental stability of the model.